Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Cohn

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Cancer|August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupLarry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.
European Journal of Cancer (Oxford, England : 1990)|December 30, 2016
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group ProjectMark A Applebaum, Zalman Vaksman, Sang Mee Lee, et al.
Cancer Letters|June 25, 2005
Epidural compression in neuroblastoma: Diagnostic and therapeutic aspectsBruno De Bernardi, Walentyna Balwierz, Joanna Bejent, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
JCO Precision Oncology|June 11, 2019
5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor PhenotypeMark A Applebaum, Erin K Barr, Jason Karpus, et al.
Pediatric Blood & Cancer|November 6, 2024
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531Julie Voeller, Howard M Katzenstein, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641Douglas R Strother, Wendy B London, Mary Lou Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2021
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology GroupMeredith S Irwin, Arlene Naranjo, Fan F Zhang, et al.
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Cancer|August 1, 2013
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupLarry L Wang, Rie Suganuma, Naohiko Ikegaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.
European Journal of Cancer (Oxford, England : 1990)|December 30, 2016
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group ProjectMark A Applebaum, Zalman Vaksman, Sang Mee Lee, et al.
Cancer Letters|June 25, 2005
Epidural compression in neuroblastoma: Diagnostic and therapeutic aspectsBruno De Bernardi, Walentyna Balwierz, Joanna Bejent, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
JCO Precision Oncology|June 11, 2019
5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor PhenotypeMark A Applebaum, Erin K Barr, Jason Karpus, et al.
Pediatric Blood & Cancer|November 6, 2024
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531Julie Voeller, Howard M Katzenstein, Arlene Naranjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641Douglas R Strother, Wendy B London, Mary Lou Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2021
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology GroupMeredith S Irwin, Arlene Naranjo, Fan F Zhang, et al.
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.
Pageof 19